Frontiers of Oncology: Lung Cancer

This event is now closed, information is displayed here for information only.

The 2018 ‘Frontiers of Oncology: Lung Cancer’ meeting will be announced in Spring 2018

but you can pre-register HERE to be advised when the programme is released.

A one day meeting held on
Tuesday 18th October 2016
The Royal College of Physicians, London, UK

Frontiers of Oncology: Lung Cancer is a one day medical education meeting which will bring together a notable faculty of Lung Cancer experts from UCL and beyond who will preview the latest advances in research, consider the likely impact on the clinic of tomorrow, and discuss and debate the pertinent issues which are affecting Oncologists across the UK and Europe.


Professor Charles Swanton
Professor Charles Swanton
Chair in Personalised Cancer Medicine
UCL Cancer Institute
Professor Siow-Ming LeeProfessor Siow-Ming Lee
Professor of Medical Oncology
University College London


The full programme is HERE

Who should attend?
This meeting is ideal for:

    • Consultants
    • GPs
    • Nurses
    • Researchers and
    • Scientists

who any healthcare professionals who have an interest in the future shape and direction of Lung Cancer research and treatment.

‘Frontiers of Oncology: Lung Cancer’ (code: 107918) has been approved for 6 credits (external) by the Federation of the Royal Colleges of Physicians of the United Kingdom.

When & Where
Tuesday 18th October 2016, 9.00am – 5.00pm

The Royal College of Physicians, London, UK
11 St Andrews Place,
Map here

The meeting costs will be underwritten by Pharmaceutical Industry sponsors and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

This meeting is organised by:

New UCL Logo2 800



and endorsed and supported by:



Frontiers of Oncology meetings are supported by educational grants from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.

The Frontiers of Oncology 2019 meetings are supported by the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.